Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

NCT01676233 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: insulin glargine (HOE901)
DRUG: insulin glargine- new formulation (HOE901)

Sponsor

Sanofi